Ergoteles’s Ovid Therapeutics OVID Stock Holding History

Ergoteles’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-75,923	Closed	-$141K	–	1632
2022 Q4	$141K	Buy	+75,923	New	+$129K	0.01%	1161
2021 Q4	–	Sell	-166,668	Closed	-$560K	–	1501
2021 Q3	$560K	Sell	166,668 -30,721	-16%	-$112K	0.02%	538
2021 Q2	$772K	Buy	+197,389	New	+$779K	0.02%	605
2020 Q4	–	Sell	-25,947	Closed	-$149K	–	848
2020 Q3	$149K	Buy	+25,947	New	+$174K	0.02%	510

Other funds holding OVID

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Ergoteles's OVID Position: Q1 2023 in Review

Ergoteles sold out of Ovid Therapeutics (OVID) in Q1 2023, closing a stake of 75,923 shares — an estimated $141K sold.

Ergoteles first reported a position in OVID in Q3 2020 and held it in 4 quarters. The position peaked at $772K in Q2 2021. 60 funds tracked by Wall St. Rank hold OVID as of Q1 2023.

Ergoteles reported no remaining Ovid Therapeutics position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 75,923 Ovid Therapeutics shares in Q1 2023, an estimated $141K.
Ergoteles first reported a position in Ovid Therapeutics in Q3 2020 and held it in 4 quarters.
Ergoteles's Ovid Therapeutics position peaked at $772K in Q2 2021.
60 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.